Project Grant P50CA275741
Award Date
9/2/24
Completion Date
8/31/29
Dollars Obligated
$4.4M
Federal Agency
National Cancer Institute
Federal Grant Program
93.397
Assistance Type
Project Grant
Place of Performance
California, USA
Similar Awards
This federal Project Grant award from the National Cancer Institute (NCI), under the Cancer Detection and Diagnosis Research program (CFDA 93.394), provides $680,433 to The Regents of the University of California, San Francisco (UCSF) to conduct research aimed at improving prognostic estimation and understanding the underlying biology of prostate cancer. The key objectives are to: 1) Evaluate the competitive and additive relationships between established genomic expression tests and pathology...
The University of California, San Francisco (UCSF) has been awarded a $1,202,087 federal Project Grant from the Department of Defense's Military Medical Research and Development program (CFDA 12.420) to investigate SSTR1 as a novel biomarker and therapeutic target in advanced prostate cancer. The award, effective July 1, 2024 through June 30, 2028, will enable UCSF researchers to conduct innovative scientific studies to develop new treatments for this challenging disease. As a leading academic...
This Project Grant award from the Department of the Army Medical Command under the Military Medical Research and Development program (CFDA 12.420) provides $1,615,000.00 to The Regents of the University of California, San Francisco (UCSF) to conduct research aimed at "DISCOVERING TRANSCRIPTIONAL DRIVERS OF THERAPY-RESISTANT METASTATIC PROSTATE CANCER". The award period runs from May 1, 2024 to April 30, 2027. As a leading academic medical center, UCSF has a strong track record of...
This federal Project Grant award for $710,980.00 from the National Cancer Institute (NCI) under the Cancer Treatment Research program (CFDA 93.395) supports research aimed at defining the molecular mechanisms and therapeutic potential of targeting the SPOP ubiquitin signaling pathway in prostate cancer. Key objectives include: Elucidating the role of the SPOP pathway regulator G3BP1 in driving prostate tumorigenesis and evaluating the ability to target this upstream axis. Establishing the...
The Department of Defense's Military Medical Research and Development program (CFDA 12.420) awarded a $1,453,501.00 Project Grant to The Regents of the University of California, San Francisco (UCSF) on June 1, 2024. The grant supports the development of "Targeted Theranostic Nanopolymers for Imaging and Alpha Radiopharmaceutical Therapy of Prostate Cancer" over a period of 3 years through May 31, 2027. As a leading academic medical center, UCSF will leverage its expertise in biomedical...
This federal Project Grant award of $571,271 from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) will fund research to develop a targeted drug conjugate for the treatment of metastatic castration-resistant prostate cancer (MCRPC). The research team at the University of Texas Health Science Center at Houston will synthesize a prostate-specific membrane antigen (PSMA)-targeted drug conjugate containing the microtubule inhibitor cryptophycin, visualize and quantify the in...
This Project Grant award from the Department of the Army Medical Command under the Military Medical Research and Development program (CFDA 12.420) provides $1,228,594.00 to the Regents of the University of California, San Francisco (UCSF) for research on bispecific antibody-drug conjugates against emerging targets in metastatic lethal prostate cancer. The award period is from April 15, 2024 to April 14, 2027. As a leading academic medical center and research institution, UCSF will leverage its...
This Project Grant award from the National Cancer Institute (CFDA 93.396 - Cancer Biology Research) provides $683,979 to Weill Medical College of Cornell University to study the role of early oncogenic drivers in maintaining lineage fidelity in prostate cancer. The key objectives are to: Define the propensity of prostate cancers with SPOP mutations to progress to specific subtypes of treatment-resistant castration-resistant prostate cancer (CRPC). Mechanistically determine the contribution of...
This Cooperative Agreement award from the Centers for Disease Control and Prevention (CDC) under the Centers for Research and Demonstration for Health Promotion and Disease Prevention program (CFDA 93.135) provides $1,050,000 to The Regents of the University of California, San Francisco (UCSF) to conduct research on patient perspectives on relabeling and pathology reporting for Grade Group 1 prostate cancer. The project will run from September 30, 2024 to September 29, 2027. As a leading...
The Regents of the University of California, San Francisco (UCSF) has been awarded a $595,160 Project Grant by the Department of Defense's Military Medical Research and Development program (CFDA 12.420) to translate a first-in-class PET radiotracer to assess ferroaddiction as a therapeutic vulnerability in advanced prostate cancer. The 3-year award, effective July 1, 2024, supports innovative biomedical research aimed at developing new diagnostic and treatment approaches for military personnel...